News
The European Lead Factory Final Project Update: Results and Impacts of a Decade of Collaborative Drug Discovery
The European Lead Factory (ELF), a flagship open innovation platform focused on finding high-quality leads for new drug discovery programs, has officially come to a close.
A public-private partnership that brought together the best of industry and academia, Lygature played a critical role in the ELF, leading the consortium with overall program management and communication – helping to ensure the initiative delivered optimal results.
Commenting on the long-running partnership, Dr Jon de Vlieger, ELF Coordinator and Strategic Director at Lygature said: “A decade of the ELF has resulted in tangible assets and impactful output. With the contributions of many partners, we have successfully shown that collaboration with different organizations through a central core team can create waves and achieve results that translate into real impact.”
The final project update, showcasing the results and impacts of 11 years of the ELF, is now available.
Acknowledgement of support
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.
This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).